Minster Pharmaceuticals, UCLA to collaborate on migraine research

By Elaine Rigoli

Tampa, Fla., May 24 - Minster Pharmaceuticals plc has entered into a collaboration with the University of California, Los Angeles (UCLA), in which UCLA will conduct studies relating to the mechanism of action of tonabersat, Minster's compound for the prevention of migraine.

The UCLA studies will look at tonabersat's influence on brain function and the biochemical events that underlie the onset of a migraine attack, Minster explained in a news release.

UCLA will fund studies examining tonabersat's ability to inhibit the intercellular propagation of astrocyte calcium waves and the possibility that the site of this inhibition is in connexin channels.

Minster said these studies will potentially reveal a fundamental mechanism in the onset and development of migraine.

This collaboration is one of a series of planned collaborations with major international institutions to define tonabersat's full therapeutic potential, the release said.

Minster, located in Essex, U.K., is a drug-development company specializing in neurological and psychiatric disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.